Maryland Tech Council Statement on Maryland Prescription Drug Affordability Board Preliminary Cost Determination

ROCKVILLE, MD – (July 29, 2025) – Kelly Schulz, CEO of the Maryland Tech Council, issued the following statement after the Maryland Prescription Drug Affordability Board (PDAB) made preliminary cost determinations on two prescription drugs, Farxiga® and Jardiance®. 

Statement from Kelly Schulz:

“The Maryland Prescription Drug Affordability Board’s current approach to drug affordability will not directly make medications more affordable for patients and could cause a chilling effect on our state’s life sciences ecosystem, which includes 2,700 companies and 54,000 workers.

“Maryland’s life sciences ecosystem is the foundation of our economy and develops therapies, cures, and treatments that millions of patients depend on. Arbitrary price controls on prescription drugs will jeopardize the life sciences industry’s ability to invest in research and clinical trials that can change lives for patients and create jobs for Maryland workers. Maryland should be encouraging investment, not potentially limiting it.

“We continue to encourage the Board to create greater opportunity for stakeholder engagement and to explore non-Upper Payment Limit alternatives to lower patients’ out of pocket costs.”  

Contacts

Media Contact
Henry Fawell
Campfire Communications
henry@campfirecomm.com
(410) 212-8468